Literature DB >> 29785566

Delineating a new feature of constitutional mismatch repair deficiency (CMMRD) syndrome: breast cancer.

Lisa Bush1, Melyssa Aronson2, Uri Tabori3, Brittany B Campbell4, Raymond B Bedgood5, Kory Jasperson6.   

Abstract

Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare autosomal recessive hereditary cancer condition, characterized by an exceptionally high risk of cancer, a propensity for childhood malignancies, and cutaneous features reminiscent of neurofibromatosis type 1 (NF1). We report on two sisters originally suspected of having CMMRD syndrome due to their history of colonic polyps and NF1 associated skin findings, both were subsequently found to have biallelic MSH6 mutations. After years of CMMRD syndrome follow-up, the proband was diagnosed with breast cancer at age 29, while her sister was diagnosed with a glioblastoma at age 27. Immunohistochemistry analysis on the breast tumor tissue revealed weak MSH6 protein staining. Exome sequencing revealed a hypermutated breast tumor and an ultra-hypermutated brain tumor. Multi-gene panel testing was also performed and revealed no additional mutations which might explain the proband's early onset breast cancer. This is the first documented case of breast cancer in an individual with CMMRD syndrome. We summarize the evidence supporting the possible association between breast cancer and biallelic MMR mutations. Healthcare providers should be aware of this possible association and follow-up appropriately for suspicious breast findings. In addition, this case highlights the need for frequent central nervous system screenings due to rapid progression of brain tumors.

Entities:  

Keywords:  CMMRD; Constitutional mismatch repair deficiency syndrome; Hereditary brain tumor; Hereditary breast cancer; Lynch syndrome; MSH6

Mesh:

Substances:

Year:  2019        PMID: 29785566     DOI: 10.1007/s10689-018-0088-0

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  21 in total

1.  Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma.

Authors:  A Borg; J Isola; J Chen; C Rubio; U Johansson; B Werelius; A Lindblom
Journal:  Int J Cancer       Date:  2000-03-15       Impact factor: 7.396

2.  A human compound heterozygote for two MLH1 missense mutations.

Authors:  P Hackman; P Tannergård; S Osei-Mensa; J Chen; M F Kane; R Kolodner; B Lambert; D Hellgren; A Lindblom
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

3.  Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.

Authors:  Doua Bakry; Melyssa Aronson; Carol Durno; Hala Rimawi; Roula Farah; Qasim Kholaif Alharbi; Musa Alharbi; Ashraf Shamvil; Shay Ben-Shachar; Matthew Mistry; Shlomi Constantini; Rina Dvir; Ibrahim Qaddoumi; Steven Gallinger; Jordan Lerner-Ellis; Aaron Pollett; Derek Stephens; Steve Kelies; Elizabeth Chao; David Malkin; Eric Bouffet; Cynthia Hawkins; Uri Tabori
Journal:  Eur J Cancer       Date:  2014-01-15       Impact factor: 9.162

4.  Risks of less common cancers in proven mutation carriers with lynch syndrome.

Authors:  Christoph Engel; Markus Loeffler; Verena Steinke; Nils Rahner; Elke Holinski-Feder; Wolfgang Dietmaier; Hans K Schackert; Heike Goergens; Magnus von Knebel Doeberitz; Timm O Goecke; Wolff Schmiegel; Reinhard Buettner; Gabriela Moeslein; Tom G W Letteboer; Encarna Gómez García; Frederik J Hes; Nicoline Hoogerbrugge; Fred H Menko; Theo A M van Os; Rolf H Sijmons; Anja Wagner; Irma Kluijt; Peter Propping; Hans F A Vasen
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

5.  Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D).

Authors:  H F A Vasen; Z Ghorbanoghli; F Bourdeaut; O Cabaret; O Caron; A Duval; N Entz-Werle; Y Goldberg; D Ilencikova; C P Kratz; N Lavoine; J Loeffen; F H Menko; M Muleris; G Sebille; C Colas; B Burkhardt; L Brugieres; K Wimmer
Journal:  J Med Genet       Date:  2014-02-20       Impact factor: 6.318

6.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

7.  Neurofibromatosis and early onset of cancers in hMLH1-deficient children.

Authors:  Q Wang; C Lasset; F Desseigne; D Frappaz; C Bergeron; C Navarro; E Ruano; A Puisieux
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

8.  Comprehensive Analysis of Hypermutation in Human Cancer.

Authors:  Brittany B Campbell; Nicholas Light; David Fabrizio; Matthew Zatzman; Fabio Fuligni; Richard de Borja; Scott Davidson; Melissa Edwards; Julia A Elvin; Karl P Hodel; Walter J Zahurancik; Zucai Suo; Tatiana Lipman; Katharina Wimmer; Christian P Kratz; Daniel C Bowers; Theodore W Laetsch; Gavin P Dunn; Tanner M Johanns; Matthew R Grimmer; Ivan V Smirnov; Valérie Larouche; David Samuel; Annika Bronsema; Michael Osborn; Duncan Stearns; Pichai Raman; Kristina A Cole; Phillip B Storm; Michal Yalon; Enrico Opocher; Gary Mason; Gregory A Thomas; Magnus Sabel; Ben George; David S Ziegler; Scott Lindhorst; Vanan Magimairajan Issai; Shlomi Constantini; Helen Toledano; Ronit Elhasid; Roula Farah; Rina Dvir; Peter Dirks; Annie Huang; Melissa A Galati; Jiil Chung; Vijay Ramaswamy; Meredith S Irwin; Melyssa Aronson; Carol Durno; Michael D Taylor; Gideon Rechavi; John M Maris; Eric Bouffet; Cynthia Hawkins; Joseph F Costello; M Stephen Meyn; Zachary F Pursell; David Malkin; Uri Tabori; Adam Shlien
Journal:  Cell       Date:  2017-10-19       Impact factor: 41.582

Review 9.  Risk of breast cancer in Lynch syndrome: a systematic review.

Authors:  Aung Ko Win; Noralane M Lindor; Mark A Jenkins
Journal:  Breast Cancer Res       Date:  2013-03-19       Impact factor: 6.466

10.  Is breast cancer a part of Lynch syndrome?

Authors:  James M Ford
Journal:  Breast Cancer Res       Date:  2012-08-22       Impact factor: 6.466

View more
  3 in total

Review 1.  The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals.

Authors:  Cristina Carrato; Carolina Sanz; Ana María Muñoz-Mármol; Ignacio Blanco; Marta Pineda; Jesús Del Valle; Estela Dámaso; Manel Esteller; Eva Musulen
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

2.  Lynch Syndrome Germline Mutations in Breast Cancer: Next Generation Sequencing Case-Control Study of 1,263 Participants.

Authors:  Aleksey G Nikitin; Daria A Chudakova; Rafael F Enikeev; Dina Sakaeva; Maxim Druzhkov; Leyla H Shigapova; Olga I Brovkina; Elena I Shagimardanova; Oleg A Gusev; Marat G Gordiev
Journal:  Front Oncol       Date:  2020-05-29       Impact factor: 6.244

3.  Does breast carcinoma belong to the Lynch syndrome tumor spectrum? - Somatic mutational profiles vs. ovarian and colorectal carcinomas.

Authors:  Noora K Porkka; Alisa Olkinuora; Teijo Kuopio; Maarit Ahtiainen; Samuli Eldfors; Henrikki Almusa; Jukka-Pekka Mecklin; Päivi Peltomäki
Journal:  Oncotarget       Date:  2020-04-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.